Latest News

  • Living Biobank Of Brain Metastasis Samples Enabling ‘Personalized Medicine 2.0’

    Diagnostics World |Researchers at the CNIO (Spanish National Cancer Research Centre) are forwarding the idea that metastasis, rather than the primary tumor, should be the focus of cancer treatment, which would both further the cause of personalized medicine and generate biomarkers of sensitivity or resistance to specific drugs.

    Dec 13, 2023
  • Finger Prick Test Aims to Simplify Childhood Tuberculosis Diagnosis

    Diagnostics World |An international research consortium led by scientists from LMU University Hospital Munich has tested a new simple, rapid tuberculosis test that uses a blood sample from the fingertip. The candidate test, called the Cepheid Mycobacterium tuberculosis Host Response prototype cartridge (MTB-HR), works by measuring a three-gene transcriptomic signature.

    Dec 12, 2023
  • Prognostic Biomarker Scores Big For High-Risk Breast Cancer Cases

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Dec 7, 2023
  • Researchers In Japan Identify High-Potential Biomarker Of Gastric Cancer

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Dec 5, 2023
  • Follow the Money: Sepsis Diagnostic Test, Expanding Cardiovascular Disease Info, Oncology, Peptide Therapeutics, CRISPR

    Diagnostics World | Cytovale will bring its rapid sepsis diagnosis test to more hospital emergency departments (ED) and health systems in the United States; Elucid intends to expand its commercialization efforts to provide physicians and patients with critical information to combat heart disease; Flashpoint Therapeutics to advance its programs on Oncology, Peptide Therapeutics, and CRISPR; more.

    Nov 30, 2023
  • Illumina Partners With Veracyte; Boston Scientific Corporation Acquires Relievant Medsystems; Oxford Nanopore Collaborates With Fabric Genomics

    Diagnostics World | Illumina enters a multi-year agreement with Veracyte to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument; Boston Scientific Corporation acquires Relievant Medsystems to add to chronic pain portfolio; Oxford Nanopore Technologies and Fabric Genomics collaborate to develop a software solution analysis and clinical reporting of rich genomic data for faster insights to support rapid disease characterization of babies and children with genetic disorders in acute settings; more.

    Nov 29, 2023
  • AI-Based Platform For Detecting AFib Put To The Test In VA Facilities

    Diagnostics World | Investigators at Cedars-Sinai Medical Center are looking to minimize the biases in the data used by artificial intelligence (AI) algorithms, most recently a deep learning model trained on nearly a million electrocardiograms (ECGs) to identify people with abnormal heart rhythms.

    Nov 28, 2023
  • For Equitable CF Screening, We Should Expand Our Definition of Pathogenic Variants

    Diagnostics World | Cystic fibrosis (CF) is one of the few genetic disorders to be considered both serious and common enough to merit universal carrier or prenatal screening. Unfortunately, though, current testing approaches are caught between evolution and revolution even as they continue to produce suboptimal results for people of non-European ancestry.

    Nov 21, 2023
  • Illumina Releases Updated TruSight Oncology Liquid Biopsy Assay

    Diagnostics World | Illumina announced a new generation of its distributed liquid biopsy assay for genomic profiling. The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that enables noninvasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood when tissue testing is not available, or to complement tissue-based testing.

    Nov 16, 2023
  • The Last Mile In Preventing A Deadly Hospital Infection

    Diagnostics World | The “power of the team approach” was on full display for a study designed to understand the contribution of asymptomatic carriers to the spread of Clostridioides difficile in hospitals.

    Nov 15, 2023
  • Illumina Launches Program to Discount Pathogen Sequencing Tools for Public Health

    Bio-IT World | Illumina has launched the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs) and reduced prices.

    Nov 13, 2023
  • Prevention Strategy For Alzheimer’s Disease Now On The Horizon

    Diagnostics World | It may be possible one day soon to prevent Alzheimer’s disease, a devastating illness currently suffered by more than 30 million people worldwide. The good news comes straight from the mouth of Randall J. Bateman, M.D., professor of neurology at Washington University School of Medicine and director of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit (DIAN-TU).

    Nov 8, 2023
  • Early Detection Of Alzheimer’s Disease From Blood A Near-Term Possibility

    Diagnostics World | Mayo Clinic and Oxford Nanopore Technologies teams up in a multi-year joint development collaboration to help improve patient care, including some of the hardest-to-characterize conditions and sequencing DNA; Walgreens and the Cardiovascular Research Foundation (CRF) collaborates to drive the PREVUE-VALVE study, which will help pave the way for the development of new therapies and tools for VHD detection and diagnosis; Genialis announces a new data-sharing collaboration with Cancer Research Horizons to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics; and more.

    Nov 7, 2023
  • Vocal Diabetic Clues Could Help Improve Dismal Diagnostic Rate

    Diagnostics World | A private biomedical engineering and biomarker research lab in Canada has succeeded in measuring what type 2 diabetes does to the body as manifested through the voice and it is “opening a new lens” to the identification of at-risk individuals and potentially the assessment of therapeutic interventions.

    Nov 2, 2023
  • Dementia-Associated Protein Provides Clues About Preeclampsia

    Diagnostics World | Researchers at the University of Western Ontario and Brown University were surprised to discover an “almost identical mechanism” appearing in the blood and placenta of women with preeclampsia as has been previously found in the brains of older individuals with Alzheimer’s disease (AD), traumatic brain injury (TBI), and vascular dementia.

    Nov 1, 2023
  • New AI Tool Uses Gene Sequencing Data To Predict Formation Site Of Cancer

    Diagnostics World | Researchers at Dana-Farber Cancer Institute and Massachusetts Institute of Technology have developed a new tool, based on artificial intelligence, that predicts the likely site of formation for cancer of unknown primary (CUP) tumors.

    Oct 31, 2023
  • Mayo Clinic And Oxford Nanopore Partner Up, Walgreens Teams Up With Cardiovascular Research Foundation, Cancer Research Horizons And Genialis Data Share

    Diagnostics World | Mayo Clinic and Oxford Nanopore Technologies teams up in a multi-year joint development collaboration to help improve patient care, including some of the hardest-to-characterize conditions and sequencing DNA; Walgreens and the Cardiovascular Research Foundation (CRF) collaborates to drive the PREVUE-VALVE study, which will help pave the way for the development of new therapies and tools for VHD detection and diagnosis; Genialis announces a new data-sharing collaboration with Cancer Research Horizons to better predict responses to KRAS inhibitors, immunotherapies, and other emerging classes of therapeutics; and more.

    Oct 26, 2023
  • Follow the Money: Harbinger Health’s Massive Cancer-Screening Platform Study, New IVD Funding for Oxford Nanopore In Vivo Reprogramming Therapies, HHS Grant For Substance Abuse, HIV Treatment

    Diagnostics World | bioMérieux further invests in Oxford Nanopore to expand in vitro diagnostics production; Harbinger Health trials blood-based cancer screening platform; HHS funds behavioral health services and HIV prevention for underserved populations; and more.

    Oct 25, 2023
  • Finding Ovarian Cancer Before It’s Too Late: Researchers Fight Deadly Disease with Early Detection

    Diagnostics World | A group of researchers at the University of California Santa Cruz, University of Arizona, and University of Illinois at Chicago have identified a candidate biomarker that may help lead to earlier detection of ovarian cancer without the need for a biopsy. They hope that gynecologists could someday look for the presence of this biomarker while performing a routine Pap smear, but additional research involving more patients is still needed.

    Oct 18, 2023
  • Proteomics Enables Vastly Improved Cardiovascular Disease Prediction

    Diagnostics World | The rise and fall of blood protein levels over time is an astonishingly good way to assess the risk of major atherosclerotic cardiovascular disease (ASCVD) events such as myocardial infarction (heart attack), as well as an ideal biomarker of the progression of disease and its regression in response to treatment

    Oct 17, 2023